Vaxdyn
PrivateLast Round
Series A
Sep 7, 2026
Total Funding Raised
$38M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Vaxdyn operates in Healthcare & Life Sciences and is based in Seville. Its latest recorded funding round was a Series A round in September 2026.
Vaxdyn is a biotechnology company that develops vaccines to prevent infections caused by drug-resistant bacteria.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vaxdyn Comparables
Compare Vaxdyn with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Immunethep | 86% | |
| Proxi Biotech | 83% | |
| Eli Lilly and Company | 83% |
For institutional investors. Book with your work email.
Vaxdyn Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 7, 2026 | ||||
| Grant | Sep 2, 2024 | ||||
| Series A | Sep 2, 2024 | ||||
| Grant | Apr 22, 2024 | ||||
| Grant | Dec 2, 2021 | ||||
Seed | Mar 8, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Vaxdyn Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Series A, Grant |
| CARB-X | Grant |
| Arcano Partners | Series A |
| Biovance Capital Partners | Series A |
| Bionova Capital | Seed |
| EIC Fund | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 7, 2026
$13M round led by Biovance Capital Partners.
- Aug 21, 2026
Monthly visitors increased 482% MoM, from 74 to 431.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingSep 7, 2026
Vaxdyn raises $12.8M Series A in Spain on Sep 7th '26, led by Biovance Capital with participation from the EIC Fund and Arcano Partners’ Impacto Andalucía fund to advance K-VAX into a first-in-human Phase 1 trial.
For institutional investors. Book with your work email.
Vaxdyn Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Vaxdyn's valuation, stock price, and market status.
Is Vaxdyn a public or private company?
Vaxdyn is a private company.
What is the current stock price of Vaxdyn?
Vaxdyn is a private company, so its shares have no public market price. Caplight tracks Vaxdyn's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vaxdyn worth (valuation)?
Valuation information for Vaxdyn is not publicly available.
Can I buy Vaxdyn stock?
Vaxdyn shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vaxdyn's last funding round?
Vaxdyn's most recent funding round was Series A on September 7, 2026.
Who are the main investors in Vaxdyn?
Key investors in Vaxdyn include European Innovation Council Fund, Biovance Capital Partners, EIC Fund.
Will Vaxdyn IPO soon?
No public IPO plans have been announced for Vaxdyn.
How can I track Vaxdyn secondary market activity?
Caplight tracks bids, offers, and trades in Vaxdyn's shares on secondary markets.